dc.contributor.author
Heeman, Fiona
dc.contributor.author
Yaqub, Maqsood
dc.contributor.author
Lopes Alves, Isadora
dc.contributor.author
Heurling, Kerstin
dc.contributor.author
Berkhof, Johannes
dc.contributor.author
Gispert, Juan Domingo
dc.contributor.author
Bullich, Santiago
dc.contributor.author
Foley, Christopher
dc.contributor.author
Lammertsma, Adriaan A.
dc.contributor.author
AMYPAD Consortium
dc.date.issued
2020-07-22T06:39:08Z
dc.date.issued
2020-07-22T06:39:08Z
dc.identifier
Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, Bullich S, Foley C, Lammertsma AA; AMYPAD Consortium. Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies. EJNMMI Res. 2019; 9(1):32. DOI: 10.1186/s13550-019-0499-4
dc.identifier
http://hdl.handle.net/10230/45152
dc.identifier
http://dx.doi.org/10.1186/s13550-019-0499-4
dc.description.abstract
Background: A long dynamic scanning protocol may be required to accurately measure longitudinal changes in amyloid load. However, such a protocol results in a lower patient comfort and scanning efficiency compared to static scans. A compromise can be achieved by implementing dual-time-window protocols. This study aimed to optimize these protocols for quantitative [18F]flutemetamol and [18F]florbetaben studies. Methods: Rate constants for subjects across the Alzheimer's disease spectrum (i.e., non-displaceable binding potential (BPND) in the range 0.02-0.77 and 0.02-1.04 for [18F]flutemetamol and [18F]florbetaben, respectively) were established based on clinical [18F]flutemetamol (N = 6) and [18F]florbetaben (N = 20) data, and used to simulate tissue time-activity curves (TACs) of 110 min using a reference tissue and plasma input model. Next, noise was added (N = 50) and data points corresponding to different intervals were removed from the TACs, ranging from 0 (i.e., 90-90 = full-kinetic curve) to 80 (i.e., 10-90) minutes, creating a dual-time-window. Resulting TACs were fitted using the simplified reference tissue method (SRTM) to estimate the BPND, outliers (≥ 1.5 × BPND max) were removed and the bias was assessed using the distribution volume ratio (DVR = BPND + 1). To this end, acceptability curves, which display the fraction of data below a certain bias threshold, were generated and the area under those curves were calculated. Results: [18F]Flutemetamol and [18F]florbetaben data demonstrated an increased bias in amyloid estimate for larger intervals and higher noise levels. An acceptable bias (≤ 3.1%) in DVR could be obtained with all except the 10-90 and 20-90-min intervals. Furthermore, a reduced fraction of acceptable data and most outliers were present for these two largest intervals (maximum percentage outliers 48 and 32 for [18F]flutemetamol and [18F]florbetaben, respectively). Conclusions: The length of the interval inversely correlates with the accuracy of the BPND estimates. Consequently, a dual-time-window protocol of 0-30 and 90-110 min (=maximum of 60 min interval) allows for accurate estimation of BPND values for both tracers. [18F]flutemetamol: EudraCT 2007-000784-19, registered 8 February 2007, [18F]florbetaben: EudraCT 2006-003882-15, registered 2006.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
EJNMMI Res. 2019; 9(1):32
dc.relation
info:eu-repo/grantAgreement/EC/H2020/115952
dc.rights
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Alzheimer’s disease
dc.subject
Florbetaben PET
dc.subject
Flutemetamol PET
dc.subject
Quantification
dc.subject
Simplified methods
dc.title
Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion